BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage
biopharmaceutical company dedicated to identifying, in-licensing and
developing promising therapeutic candidates, announced today that it
will release its unaudited financial results for the quarter ended
September 30, 2014 on Monday, November 10, 2014, before the U.S. markets
open.
The Company will host a conference call on Monday, November 10 at 10:00
a.m. EST, featuring remarks by Kinneret Savitsky, Ph.D., Chief Executive
Officer of BioLineRx, and Philip Serlin, Chief Financial and Operating
Officer of BioLineRx.
The conference call will be available via webcast and can be accessed
through the Investor Relations section of BioLineRx’s website, www.biolinerx.com.
A presentation will be provided on BioLineRx’s website, to accompany
management’s remarks during the conference call. Please allow extra time
prior to the call to visit the site and download any necessary software
to listen to the live broadcast. To dial into the conference call,
please dial 1-866-229-7198 from the U.S. or +972-3-918-0685
internationally.
A replay of the conference call will be available approximately two
hours after completion of the live conference call at www.biolinerx.com.
A dial-in replay of the call will also be available until November 13,
2014. To access the replay, please dial 1-888-295-2634 from the U.S. or
+972-3-925-5937 internationally.
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based
in Israel, develops them through pre-clinical and/or clinical stages,
and then partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a
pivotal CE-Mark registration trial scheduled for completion in mid-2015;
BL-8040, a cancer therapy platform, which is in the midst of a Phase 2
study for acute myeloid leukemia (AML) as well as a Phase 1 study for
stem cell mobilization; and BL-7010 for celiac disease, which is in the
final stages of a Phase 1/2 study.
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s SEC documents, press releases, and events.
BioLineRx’s IR app is available on the iTunes App Store as well as
the Google Play Store.
Copyright Business Wire 2014